# A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma

> **NCT05220124** · PHASE4 · UNKNOWN · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 190 (estimated)

## Conditions studied

- Bladder Urothelial Carcinoma

## Interventions

- **DRUG:** Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)

## Key facts

- **NCT ID:** NCT05220124
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-05
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-11-30
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2022-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05220124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05220124, "A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05220124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*